Establishment Labs [ESTA] vs Abbott Laboratories [ABT] Detailed Stock Comparison
Establishment Labs
NASDAQ
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Establishment Labs wins in 3 metrics, Abbott Laboratories wins in 15 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Establishment Labs | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -14.55 | 16.56 | Establishment Labs |
| Price-to-Book Ratio | 50.89 | 4.54 | Abbott Laboratories |
| Debt-to-Equity Ratio | 993.34 | 26.50 | Abbott Laboratories |
| PEG Ratio | 1.80 | 0.45 | Abbott Laboratories |
| EV/EBITDA | -24.62 | 20.62 | Establishment Labs |
| Profit Margin (TTM) | -49.89% | 32.43% | Abbott Laboratories |
| Operating Margin (TTM) | -27.50% | 19.73% | Abbott Laboratories |
| EBITDA Margin (TTM) | N/A | 19.73% | N/A |
| Return on Equity | -261.18% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | -12.78% | 6.62% | Abbott Laboratories |
| Free Cash Flow (TTM) | $-74.08M | $6.35B | Abbott Laboratories |
| Dividend Yield | N/A | 1.28% | N/A |
| 1-Year Return | -4.40% | 17.66% | Abbott Laboratories |
| Price-to-Sales Ratio (TTM) | 6.53 | 5.33 | Abbott Laboratories |
| Enterprise Value | $1.33B | $236.19B | Abbott Laboratories |
| EV/Revenue Ratio | 7.50 | 5.48 | Abbott Laboratories |
| Gross Profit Margin (TTM) | 68.76% | 56.44% | Establishment Labs |
| Revenue per Share (TTM) | $6 | $25 | Abbott Laboratories |
| Earnings per Share (Diluted) | $-3.08 | $7.97 | Abbott Laboratories |
| Beta (Stock Volatility) | 0.83 | 0.71 | Abbott Laboratories |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Establishment Labs vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Establishment Labs | 9.10% | 13.88% | 0.39% | 18.43% | 23.94% | -3.62% |
| Abbott Laboratories | 0.45% | 0.64% | 5.46% | 0.83% | -1.75% | 16.88% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Establishment Labs | -4.40% | -33.19% | 147.95% | 65.37% | 65.37% | 65.37% |
| Abbott Laboratories | 17.66% | 30.12% | 19.68% | 188.11% | 454.54% | 517.85% |
Performance & Financial Health Analysis: Establishment Labs vs Abbott Laboratories
| Metric | ESTA | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $1.16B | $229.74B |
| Market Cap Category | Small cap | Mega cap |
| 10 Day Avg. Volume | 543,540 | 5,726,190 |
| 90 Day Avg. Volume | 416,250 | 7,154,530 |
| Last Close | $43.64 | $132.59 |
| 52 Week Range | $26.56 - $50.85 | $110.86 - $141.23 |
| % from 52W High | -14.18% | -6.12% |
| All-Time High | $93.80 (Apr 18, 2022) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -53.48% | -7.02% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.16% | 0.07% |
| Quarterly Earnings Growth | 0.16% | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | -0.50% | 0.32% |
| Operating Margin (TTM) | -0.28% | 0.20% |
| Return on Equity (TTM) | -2.61% | 0.31% |
| Debt to Equity (MRQ) | 993.34 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.79 | $29.05 |
| Cash per Share (MRQ) | $1.89 | $4.18 |
| Operating Cash Flow (TTM) | $-72,688,000 | $9.04B |
| Levered Free Cash Flow (TTM) | $-39,815,124 | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.28% |
| Last 12-Month Dividend | N/A | $1.69 |
Valuation & Enterprise Metrics Analysis: Establishment Labs vs Abbott Laboratories
| Metric | ESTA | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -14.55 | 16.56 |
| Forward P/E | -24.24 | 25.58 |
| PEG Ratio | 1.80 | 0.45 |
| Price to Sales (TTM) | 6.53 | 5.33 |
| Price to Book (MRQ) | 50.89 | 4.54 |
| Market Capitalization | ||
| Market Capitalization | $1.16B | $229.74B |
| Enterprise Value | $1.33B | $236.19B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.50 | 5.48 |
| Enterprise to EBITDA | -24.62 | 20.62 |
| Risk & Other Metrics | ||
| Beta | 0.83 | 0.71 |
| Book Value per Share (MRQ) | $0.79 | $29.05 |
Financial Statements Comparison: Establishment Labs vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ESTA | ABT |
|---|---|---|
| Revenue/Sales | $51.30M | $10.36B |
| Cost of Goods Sold | $16.03M | $4.47B |
| Gross Profit | $35.27M | $5.89B |
| Research & Development | $5.20M | $716.00M |
| Operating Income (EBIT) | $-14.11M | $1.69B |
| EBITDA | $-7.04M | $2.66B |
| Pre-Tax Income | $-15.59M | $1.78B |
| Income Tax | $1.00M | $453.00M |
| Net Income (Profit) | $-16.59M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ESTA | ABT |
|---|---|---|
| Cash & Equivalents | $69.18M | $6.53B |
| Total Current Assets | $231.70M | $23.15B |
| Total Current Liabilities | $69.04M | $13.00B |
| Long-Term Debt | $224.14M | $12.74B |
| Total Shareholders Equity | $38.55M | $49.06B |
| Retained Earnings | $-465.40M | $47.72B |
| Property, Plant & Equipment | $5.19M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ESTA | ABT |
|---|---|---|
| Operating Cash Flow | $-24.24M | $1.42B |
| Capital Expenditures | $-753,000 | $-484.00M |
| Free Cash Flow | $-21.75M | $933.00M |
| Debt Repayment | N/A | $-1.00B |
| Common Stock Repurchase | N/A | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | ESTA | ABT |
|---|---|---|
| Shares Short | 4.76M | 18.33M |
| Short Ratio | 14.57 | 2.44 |
| Short % of Float | 0.24% | 0.01% |
| Average Daily Volume (10 Day) | 543,540 | 5,726,190 |
| Average Daily Volume (90 Day) | 416,250 | 7,154,530 |
| Shares Outstanding | 28.79M | 1.73B |
| Float Shares | 16.95M | 1.73B |
| % Held by Insiders | 0.11% | 0.01% |
| % Held by Institutions | 1.05% | 0.81% |
Dividend Analysis & Yield Comparison: Establishment Labs vs Abbott Laboratories
| Metric | ESTA | ABT |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.69 |
| Last 12-Month Dividend Yield | N/A | 1.28% |
| 3-Year Avg Annual Dividend | N/A | $1.92 |
| 3-Year Avg Dividend Yield | N/A | 0.49% |
| 3-Year Total Dividends | N/A | $5.77 |
| Ex-Dividend Date | N/A | Jan 15, 2025 |